Literature DB >> 8824314

Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein.

M L Oster-Granite1, D L McPhie, J Greenan, R L Neve.   

Abstract

The molecular basis for the degeneration of neurons and the deposition of amyloid in plaques and in the cerebrovasculature in Alzheimer's disease (AD) is incompletely understood. We have proposed that one molecule common to these abnormal processes is a fragment of the Alzheimer amyloid precursor protein (APP) comprising the C-terminal 100 amino acids of this molecule (APP-C100). We tested this hypothesis by creating transgenic mice expressing APP-C100 in the brain. We report here that aging (18-28 month) APP-C100 transgenic mice exhibit profound degeneration of neurons and synapses in Ammon's horn and the dentate gyrus of the hippocampal formation. Of the 106 transgenic mice between 8 and 28 months of age that were examined, all of those older than 18 months displayed severe hippocampal degeneration. The numerous degenerating axonal profiles contained increased numbers of neurofilaments, whorls of membrane, and accumulations of debris resembling secondary lysosomes near the cell body. The dendrites of degenerating granule and pyramidal cells contained disorganized, wavy microtubules. Cerebral blood vessels had thickened refractile basal laminae, and microglia laden with debris lay adjacent to larger venous vessels. Mice transgenic for Flag-APP-C100 (in which the hydrophilic Flag tag was fused to the N terminus of APP-C100) showed a similar degree of neurodegeneration in the hippocampal formation as early as 12 months of age. The 45 control mice displayed only occasional necrotic cells and no extensive cell degeneration in the same brain regions. These findings show that APP-C100 is capable of causing some of the neuropathological features of AD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824314      PMCID: PMC6579256     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding.

Authors:  M R Kozlowski; A Spanoyannis; S P Manly; S A Fidel; R L Neve
Journal:  J Neurosci       Date:  1992-05       Impact factor: 6.167

3.  Synaptic loss in Alzheimer's disease and other dementias.

Authors:  J E Hamos; L J DeGennaro; D A Drachman
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

4.  Brain transplants of cells expressing the carboxyl-terminal fragment of the Alzheimer amyloid protein precursor cause specific neuropathology in vivo.

Authors:  R L Neve; A Kammesheidt; C F Hohmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

5.  The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects.

Authors:  L I Benowitz; W Rodriguez; P Paskevich; E J Mufson; D Schenk; R L Neve
Journal:  Exp Neurol       Date:  1989-12       Impact factor: 5.330

6.  The development of the cerebellar cortex of the Syrian hamster, Mesocricetus auratus. Foliation, cytoarchitectonic, Golgi, and electron microscopic studies.

Authors:  M L Oster-Granite; R M Herndon
Journal:  J Comp Neurol       Date:  1976-10-15       Impact factor: 3.215

7.  Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease.

Authors:  E Masliah; M Mallory; T Deerinck; R DeTeresa; S Lamont; A Miller; R D Terry; B Carragher; M Ellisman
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

8.  Deposits of amyloid beta protein in the central nervous system of transgenic mice.

Authors:  D O Wirak; R Bayney; T V Ramabhadran; R P Fracasso; J T Hart; P E Hauer; P Hsiau; S K Pekar; G A Scangos; B D Trapp
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

9.  Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease.

Authors:  S M de la Monte
Journal:  Ann Neurol       Date:  1989-05       Impact factor: 10.422

10.  Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters.

Authors:  D C Górecki; A P Monaco; J M Derry; A P Walker; E A Barnard; P J Barnard
Journal:  Hum Mol Genet       Date:  1992-10       Impact factor: 6.150

View more
  55 in total

1.  The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus.

Authors:  Y Gao; S W Pimplikar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

Review 3.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

4.  Tuning of Glutamate, But Not GABA, Release by an Intrasynaptic Vesicle APP Domain Whose Function Can Be Modulated by β- or α-Secretase Cleavage.

Authors:  Wen Yao; Marc D Tambini; Xinran Liu; Luciano D'Adamio
Journal:  J Neurosci       Date:  2019-06-24       Impact factor: 6.167

5.  Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP.

Authors:  M Dumont; R Lalonde; J-F Ghersi-Egea; K Fukuchi; C Strazielle
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

6.  Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease.

Authors:  Maite Solas; Bárbara Aisa; María C Mugueta; Joaquín Del Río; Rosa M Tordera; María J Ramírez
Journal:  Neuropsychopharmacology       Date:  2010-02-24       Impact factor: 7.853

Review 7.  Advances and challenges in the prevention and treatment of Alzheimer's disease.

Authors:  R Diaz Brinton; R S Yamazaki
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 8.  Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo.

Authors:  Mike Beck; Volker Bigl; Steffen Rossner
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

9.  Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path.

Authors:  J D Buxbaum; G Thinakaran; V Koliatsos; J O'Callahan; H H Slunt; D L Price; S S Sisodia
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.

Authors:  L W Jin; M G Hearn; C E Ogburn; N Dang; D Nochlin; W C Ladiges; G M Martin
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.